Holen Sie sich die Stockscreener-App
58.62
2.44%
1.3384
Schlusskurs vom Vortag:
$57.28
Offen:
$57.08
24-Stunden-Volumen:
233.21K
Relative Volume:
0.26
Marktkapitalisierung:
$1.19B
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-40.15
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
+6.98%
1M Leistung:
+4.84%
6M Leistung:
+567.58%
1J Leistung:
+5,710%
1-Tages-Spanne:
$56.01
$58.83
1-Wochen-Bereich:
$53.55
$58.94
52-Wochen-Spanne:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
58.60 | 1.17B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy - sharewise.com
Nektar Therapeutics $NKTR Shares Sold by 22NW LP - MarketBeat
Is Nektar Therapeutics (NKTR) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance UK
Nektar Therapeutics (NKTR) Price Target Increased by 14.31% to 109.43 - Nasdaq
NKTRNektar Therapeutics Latest Stock News & Market Updates - Stock Titan
Stonepine Capital Management LLC Makes New Investment in Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Nektar Therapeutics stock maintain dividend yieldOptions Play & Real-Time Volume Trigger Notifications - Newser
Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterPortfolio Performance Summary & Weekly High Return Stock Opportunities - Newser
Will Nektar Therapeutics stock benefit from green energy trendsTrade Signal Summary & Daily Oversold Stock Bounce Ideas - Newser
How robust is Nektar Therapeutics (ITH0) stock financial positionAnalyst Upgrade & Risk Controlled Daily Trade Plans - Newser
How strong dollar benefits Nektar Therapeutics (ITH0) stockTrade Risk Assessment & Long-Term Safe Investment Ideas - Newser
NKTR SEC FilingsNektar Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Will Nektar Therapeutics stock benefit from upcoming earnings reports2025 Top Gainers & Verified Momentum Stock Alerts - Newser
Is Nektar Therapeutics stock attractive for ETFs2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 7.5%What's Next? - MarketBeat
Colorectal Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeu - Barchart.com
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - The Manila Times
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - GlobeNewswire Inc.
Nektar Therapeutics gains amid takeover speculation - MSN
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $102 - 富途牛牛
Latex Allergy Market Covering Prime Factors and Competitive - openPR.com
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade - Finviz
Nektar Therapeutics Reveals Promising Phase 2b Trial Results - MSN
Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap UpShould You Buy? - MarketBeat
Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus
Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 - GuruFocus
Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance
Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa
Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks
Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus
Citi Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Portland Topic NEKTAR THERAPEUTICS | News, Weather, Sports, Breaking News - KATU
Howard Robin Sells 2,207 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire) - Aktiellt
Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com
Nektar Therapeutics CLO Wilson sells $34,196 in shares - Investing.com
VP Zalevsky Acquires 1,509 Of Nektar Therapeutics [NKTR] - TradingView
VP Wilson Surrenders 630 Of Nektar Therapeutics [NKTR] - TradingView
CEO Robin Files To Sell 2,207 Of Nektar Therapeutics [NKTR] - TradingView
VP Wilson Files To Sell 630 Of Nektar Therapeutics [NKTR] - TradingView
VP Zalevsky Files To Sell 1,157 Of Nektar Therapeutics [NKTR] - TradingView
How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition - simplywall.st
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
Would You Still Hold Nektar Therapeutics Stock If It Fell Another 30%? - Trefis
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):